208 related articles for article (PubMed ID: 29544762)
21. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
Seliem RM; Freeman JK; Steingart RH; Hasserjian RP
Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
[TBL] [Abstract][Full Text] [Related]
22. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
Hiraga J; Tomita A; Sugimoto T; Shimada K; Ito M; Nakamura S; Kiyoi H; Kinoshita T; Naoe T
Blood; 2009 May; 113(20):4885-93. PubMed ID: 19246561
[TBL] [Abstract][Full Text] [Related]
23. Improved Outcome of Newly Diagnosed Childhood Mature B-Cell Lymphoma/Leukemia With High Tumor Burden Treated With BFM95-based Protocol Combining Rituximab: A Report From Shanghai, China.
Fu Y; Wang H; Zhai X; Qian X; Meng J; Miao H; Zhu X; Yu Y; Lu F
J Pediatr Hematol Oncol; 2019 Apr; 41(3):170-174. PubMed ID: 30664102
[TBL] [Abstract][Full Text] [Related]
24. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
[TBL] [Abstract][Full Text] [Related]
25. Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab.
Haen SP; Schmiedel BJ; Rothfelder K; Schmied BJ; Dang TM; Mirza N; Möhle R; Kanz L; Vogel W; Salih HR
Oncotarget; 2016 Mar; 7(11):13013-30. PubMed ID: 26887048
[TBL] [Abstract][Full Text] [Related]
26. Rituximab in the management of acute lymphoblastic leukemia.
Levato L; Molica S
Expert Opin Biol Ther; 2018 Feb; 18(2):221-226. PubMed ID: 29310477
[TBL] [Abstract][Full Text] [Related]
27. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
29. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.
Ceppi F; Weitzman S; Woessmann W; Davies K; Lassaletta A; Reismüller B; Mellgren K; Uyttebroeck A; Maia I; Abdullah S; Miakova N; Glaser D; Cohn R; Abla O; Attarbaschi A; Alexander S
Am J Hematol; 2016 May; 91(5):486-91. PubMed ID: 26872652
[TBL] [Abstract][Full Text] [Related]
31. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
32. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
Forero-Castro M; Robledo C; Benito R; Bodega-Mayor I; Rapado I; Hernández-Sánchez M; Abáigar M; Maria Hernández-Sánchez J; Quijada-Álamo M; María Sánchez-Pina J; Sala-Valdés M; Araujo-Silva F; Kohlmann A; Luis Fuster J; Arefi M; de Las Heras N; Riesco S; Rodríguez JN; Hermosín L; Ribera J; Camos Guijosa M; Ramírez M; de Heredia Rubio CD; Barragán E; Martínez J; Ribera JM; Fernández-Ruiz E; Hernández-Rivas JM
Br J Cancer; 2017 Jul; 117(2):256-265. PubMed ID: 28557976
[TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia.
Casale F; D'Angelo V; Addeo R; Caraglia M; Crisci S; Rondelli R; Di Tullio MT; Indolfi P
Oncol Rep; 2004 Dec; 12(6):1201-7. PubMed ID: 15547738
[TBL] [Abstract][Full Text] [Related]
34. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
Hong J; Park S; Park J; Jang SJ; Ahn HK; Sym SJ; Cho EK; Shin DB; Lee JH
Ann Hematol; 2012 Dec; 91(12):1897-906. PubMed ID: 22864685
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
Coso D; Sebban C; Boulat O; Biron P; Rey J; Aurran T; Chabannon C; Xerri L; Chetaille B; Esterni B; Ivanov V; Stoppa AM; Schiano de Collela JM; Gastaut JA; Maraninchi D; Bouabdallah R
Bone Marrow Transplant; 2006 Aug; 38(3):217-22. PubMed ID: 16770316
[TBL] [Abstract][Full Text] [Related]
36. [Clinical effect of CCLG-ALL2008 regimen in treatment of children and adolescents aged >10 years with acute lymphoblastic leukemia].
Lan Y; Chen XJ; Zou Y; Ruan M; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2019 May; 21(5):405-410. PubMed ID: 31104652
[TBL] [Abstract][Full Text] [Related]
37. Treatment outcome of pediatric acute lymphoblastic leukemia in Yeungnam region: Multicenter retrospective study of Study Alliance of Yeungnam Pediatric Hematology-Oncology (SAYPH).
Yang EJ; Park KM; Lee JM; Hah JO; Park SK; Suh JK; Kim JY; Lee KS; Park J; Park ES; Lim J; Shim YJ; Kim HS; Kong SG; Chueh H; Choi EJ; Park JA; Lim YT
Pediatr Hematol Oncol; 2018 May; 35(4):276-287. PubMed ID: 30633619
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
39. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology.
Ribera JM; Ortega JJ; Oriol A; Fontanillas M; Hernández-Rivas JM; Brunet S; García-Conde J; Maldonado J; Zuazu J; Gardella S; Besalduch J; León P; Macià J; Domingo-Albós A; Feliu E; San Miguel JF
Haematologica; 1998 Mar; 83(3):222-30. PubMed ID: 9573676
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib and rituximab in de novo adolescent/adult CD20-positive, Ph-negative pre-B-cell acute lymphoblastic leukemia.
Jain H; Sengar M; Goli VB; Thorat J; Tembhare P; Shetty D; Bonda VNA; Nayak L; Subramanian PG; Bagal B; Patkar N; Sharma N; Gupta H; Gujral S
Blood Adv; 2021 Sep; 5(17):3436-3444. PubMed ID: 34461632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
